BioSpace News Archive

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Cyrus Arman as President effective July 9, 2022.

BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, President and Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be participating in the Benzinga All Access event taking place on July 15, 2022.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has finalized a supply agreement with Bloom Psychedelic Therapy And Research Centre (“Bloom”), a Calgary-based provider of mental health services, including psychedelic-assisted therapies employing ketamine treatments.

Researchers from the Center for Applied Genomics (CAG) at Children’s Hospital of Philadelphia (CHOP) have developed an algorithm that uses existing electronic health records to distinguish patients with attention-deficit/hyperactivity disorder (ADHD).

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC), a global provider of financial services and healthcare software and software-enabled services, will announce its financial results for second quarter ended June 30, 2022 after the close of the market on Wednesday, July 27, 2022.

Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the peer-reviewed journal publication of the findings from a survey of Directors of Nursing (DONs) in U.S. long-term care settings.

QSAM Biosciences Inc. (OTCQB: QSAM) (the “Company”), a company developing next-generation targeted therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®).

A sample of a new recombinant variant of SARS-CoV-2 virus, called Omicron XE, has been identified for the first time in the Miami-Dade area by a partner of AHF’s SARS-CoV-2 Genomic Sequencing Fund.

The global medical aesthetic devices market size is expected to reach USD 34.54 Billion in 2030 and register a revenue CAGR of 11.08% over the forecast period, according to latest report by Reports and Data.